Catalent to Partner with Cybin for Fast-Dissolve Formulation of Psychiatric Disorders Treatment

BioPharm International Editors

Cybin will use Catalent’s Zydis orally disintegrating tablet technology for the delivery of its novel deuterated tryptamine, CYB003, a potential therapy for treatment-resistant psychiatric disorders.

Catalent announced on March 22, 2021 that it has entered into an agreement with Cybin, a Canadian biotech company focused on psychedelic therapeutics, to use Catalent’s Zydis orally disintegrating tablet (ODT) technology for the delivery of Cybin’s novel deuterated tryptamine, CYB003, a potential therapy for treatment-resistant psychiatric disorders.

Catalent’s Zydis technology formulates a freeze-dried tablet that dissolves in the mouth without water, allowing for pre-gastric delivery of CYB003 and the prevention of first pass metabolism, thus improving the pharmacokinetic profile of the drug, Catalent said in a company press release. Due to begin in April 2021, the agreement will include feasibility studies for the manufacturing and analytical testing of ODT doses containing varying amounts of CYB003, alongside different excipients.

“We look forward to working with Cybin to potentially develop a novel and fast-acting therapy for treatment-resistant psychiatric disorders,” said Jonathan Arnold, president of Oral and Specialty Delivery at Catalent, in the press release. “The Zydis platform is an ideal technology to leverage for this type of drug formulation, as pre-gastric absorption is crucial for efficacy.”

“We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of CYB003, recently acquired as part of our acquisition of Adelia Therapeutics,” added Doug Drysdale, Cybin’s CEO, in the press release. “Our focus on reducing the need for health system resources, such as in-clinic therapist time, is an important part of our goal to create scalable, more accessible treatments for mental health disorders.”

Source: Catalent